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Abstract
Background and Aims
Corticosteroids are effective for the short-term treatment of inflammatory bowel disease
(IBD). Long-term use, however, is associated with significant adverse effects. To define the:
(1) frequency and duration of corticosteroid use, (2) frequency of escalation to corticoste-
roid-sparing therapy, (3) rate of complications related to corticosteroid use, (4) rate of appro-
priate bone density measurements (dual energy X-ray absorptiometry [DEXA] scans), and
(5) factors associated with escalation and DEXA scans.
Methods
Retrospective review of Veterans Health Administration (VHA) data from 2002–2010.
Results
Of the 30,456 Veterans with IBD, 32% required at least one course of corticosteroids during
the study time period, and 17% of the steroid users had a prolonged course. Among these
patients, only 26.2% underwent escalation of therapy. Patients visiting a gastroenterology
(GI) physician were significantly more likely to receive corticosteroid-sparing medications.
Factors associated with corticosteroid-sparing medications included younger age (OR =
0.96 per year,95%CI:0.95, 0.97), male gender (OR = 2.00,95%CI:1.16,3.46), GI visit during
the corticosteroid evaluation period (OR = 8.01,95%CI:5.85,10.95) and the use of
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continuous corticosteroids vs. intermittent corticosteroids (OR = 2.28,95%CI:1.33,3.90).
Rates of complications per 1000 person-years after IBD diagnosis were higher among corti-
costeroid users (venous thromboembolism [VTE] 9.0%; fragility fracture 2.6%; Infections
54.3) than non-corticosteroid users (VTE 4.9%; fragility fracture 1.9%; Infections 26.9).
DEXA scan utilization rates among corticosteroid users were only 7.8%.
Conclusions
Prolonged corticosteroid therapy for the treatment of IBD is common and is associated with
significant harm to patients. Patients with prolonged use of corticosteroids for IBD should be
referred to gastroenterology early and universal efforts to improve the delivery of high qual-
ity care should be undertaken.
Introduction
Corticosteroids are powerful, non-selective systemic anti-inflammatory drugs that are fre-
quently used to treat autoimmune conditions. In inflammatory bowel disease (IBD), corticoste-
roids are the mainstay of “rescue” therapy for patients who are experiencing a disease flare.
Despite the efficacy of these medications in the short-term, corticosteroids are known to cause
serious adverse effects with long term use including bone loss [1], venous thromboembolism
(VTE) [2] and poor wound healing [3]. Corticosteroids often lead to rapid resolution of IBD
symptoms, which aligns with patient preferences for treatment. However, this may lead to
inappropriate use of these medications for maintenance when other treatment options may be
better in the longer-term. Escalation of therapy to corticosteroid-sparing maintenance therapy
such as immunomodulators [4, 5] or biological agents [6, 7] can improve disease outcomes and
avoid the complications of prolonged steroid use. Underutilization of corticosteroid-sparing
medications and failure to monitor for complications of corticosteroid use have motivated pro-
fessional subspecialty societies to advocate for reduction in corticosteroid use and early initia-
tion of corticosteroid-sparing therapy [8]. Indeed, early use of corticosteroid-sparing
medications is now viewed as an increasingly important measure of the quality of IBD care [9].
These measures of the quality of the process of IBD care are aimed at optimizing medication
use and improving patient safety by minimizing exposure to medications associated with both
short and long term complications [10]. According to Plevy et al. patients with two corticoste-
roid courses within one year should escalate to corticosteroid-sparing maintenance therapy
[11]. The American Gastroenterological Association (AGA) recommends dual X-ray absorpti-
ometry (DEXA) scan evaluation of bone density in any patient on corticosteroids for at least 3
months or recurrent courses, any male with IBD over the age of 50 or any post-menopausal
female. [12, 13].
However, little is known about the frequency of corticosteroid use, the frequency of escala-
tion to corticosteroid-sparing therapy among corticosteroid users and the rate of complications
associated with corticosteroid use. The Veterans Health Administration (VHA) provides a
unique opportunity to evaluate and study corticosteroid use due to the large number of Veter-
ans with IBD in this population and the availability of detailed electronic medical record data,
including medication use. Understanding the link between processes of care (corticosteroid-
sparing maintenance use) and outcomes (rate of corticosteroid complications) is particularly
important in an era where Accountable Care Organizations (ACOs) will emphasize the deliv-
ery of high quality care and where there may be an increasing push to tie process measures to
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reimbursement. The aims of this study were to quantify: (1) frequency and duration of cortico-
steroid use in a national cohort of IBD patients in the VHA; (2) the frequency of appropriate
escalation to corticosteroid-sparing maintenance therapy; (3) the rate of complications related
to corticosteroid use, (4) the rate of appropriate bone density measurements (DEXA scans),
and (5) factors associated with escalation and DEXA scans.
Methods
Overview
We used an Institutional Review Board (IRB) approved, national Veterans Health Administra-
tive electronic data to conduct a retrospective cohort study of patients with inflammatory
bowel diseases. Patients were identified using previously validated algorithms based on a com-
bination of inpatient and outpatient International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) codes for Crohn’s disease (CD 555.x), and ulcerative colitis
(UC 556.x) [14]. Patients were selected for inclusion if they had two or more of these ICD-
9-CM codes during at least two clinical encounters between 2002–2009, with at least one of
these encounters being an outpatient visit. This approach has a positive predictive value for
Crohn’s disease of 0.84 and a positive predictive value for UC of 0.91 in the VHA [14]. Veter-
ans were classified as CD if all ICD-9-CM codes were 555.x and UC if all codes were 556.x and
the remaining Indeterminate colitis (IC). The date of the first encounter with an IBD ICD-
9-CM code was considered the Veterans “IBD index date” for study purposes. Patients were
identified with an IBD diagnosis between 2002 and 2009 and monitored for corticosteroid use
during 2002–2010. We also extracted data on medication use, imaging, and visits for gastroen-
terology (GI) specialty care.
Data On Medication Use and Gastroenterology Specialty Care Visits
We extracted data on filled prescriptions for both oral and intravenous corticosteroids of vari-
ous generic names (Appendix A in S1 Appendices) from the VHA Decision Support Systems
(DSS) National Data Extraction data source. We also determined the indication for corticoste-
roids by searching for ICD-9-CM codes for a variety of common inflammatory comorbid con-
ditions in the 7 days prior to the prescription fill date (Appendix B in S1 Appendices). In
addition, we excluded corticosteroid dose packs and fills that were short-term or low dose (fills
of 10 mg for two weeks or less, and fills where the dose was2 mg for more than one week). In
order to ensure the accuracy of this administrative dataset, manual chart review was performed
to validate each corticosteroid prescription for IBD within 3 selected VHA facilities in Veterans
Integrated Service Network (VISN) 11 (Ann Arbor, MI; Battle Creek, MI; and Saginaw, MI) in
addition to an ~10% random sample of other VHA facilities.
Outcome Variable Definitions
Corticosteroid User Groups. The primary outcome of interest was the use of corticoste-
roids in Veterans with IBD over the study period. Additional analyses were also performed to
describe the patterns of corticosteroids use and are presented in the Supplementary Results
“Patterns of Corticosteroid Use” in S1 Tables. Corticosteroid users were classified into continu-
ous corticosteroid users (CS), intermittent corticosteroid users (IS), or any corticosteroid users
(AS), according to the specifications outlined below. We also examined the use of corticoste-
roids for other conditions (OS).
We used the date of first prescription of corticosteroids within our study period as the index
date. CS was defined as patients who were initiated on corticosteroids and treated for up to 90
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days (at least 10 mg of corticosteroids for 2 weeks) and subsequently required corticosteroids
again within 90-days. IS was defined as those who were initiated on corticosteroids and treated
for up to 90 days, then had at least 90 days without steroids, but subsequently required addi-
tional steroids within the 365-day evaluation period after initiation of corticosteroids. Figs 1
and 2 illustrate the definitions of CS and IS, respectively. We excluded patients from the CS or
IS if they were prescribed any corticosteroid-sparing medication during the 365 days prior to
the initiation of second dose of corticosteroids and defined these patients as AS. OS comprised
of patients who required at least one corticosteroid prescription for a non-IBD condition.
Rate of Escalation to Corticosteroid-sparing Therapy for IBD. Our primary analysis
involved examining the rate of escalation of therapy among Veterans that were prescribed cor-
ticosteroids for their IBD (CS, IS, AS). Escalation of therapy was defined as the introduction of
a corticosteroid-sparing medication (immunosuppressant or anti-tumor necrosis factor [anti-
TNF], or a combination of an anti-TNF and an immunomodulators if they were started within
90-days of each other) during the evaluation period of 365-days after the corticosteroid fill. See
Figs 1 and 2 for an illustration of the therapeutic escalation for CS and IS.
Corticosteroid-Associated Complications in Veterans with IBD. In order to compare
complication rates related to corticosteroids and IBD, we examined rates of venous thrombo-
embolism (VTE), fragility fractures and infections among veterans who never received cortico-
steroids and patients who received any corticosteroids for their IBD (CS, IS, AS). The ICD-
9-CM codes used to identify VTE, fragility fractures and infections are included in Appendix C
in S1 Appendices. Complication rates were examined during three periods: 1) the year prior to
the study period index IBD diagnosis, 2) the year after study period index IBD diagnosis (or to
the corticosteroid initiation date in the event that corticosteroids were initiated within one year
after IBD diagnosis) and 3) year after initiation of corticosteroids for the corticosteroid group.
Fig 1. Escalation to corticosteroid-sparing therapy for Veterans who were continuous corticosteroid
users (CS).
doi:10.1371/journal.pone.0158017.g001
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Healthcare Maintenance: DEXA Scan Use in Veterans with IBD on Corticosteroids. To
examine healthcare maintenance we identified DEXA scans performed within 1 year after the
use of corticosteroids using Current Procedural Terminology (CPT)codes (pre-2006) 76075
and (post-2006) 77080. In order to compare utilization of corticosteroid-related healthcare
maintenance, we determined the frequency of DEXA scans among all patients (CS, IS, AS and
OS) who were on corticosteroids and those who were not. We further subdivided the analysis
by age less than and greater than 50 as the AGA guidelines recommend DEXA scans for all
IBD patients above the age of 50 regardless of corticosteroid utilization.
Ethics Statement. The work described was approved by the Research and Development
committee at VA Ann Arbor Health Care System. A waiver of authorization was approved for a
retrospective review of existing medical record data. All data was de-identified prior to analysis.
Statistical Analysis
Descriptive statistics were used to compare patient characteristics among the corticosteroid
and non-corticosteroid groups comparing the patient age and whether or not a visit with a GI
specialist occurred. Demographic and clinical variables were compared between the corticoste-
roid groups and additional supplementary analysis was done among the various patterns of
corticosteroid users (CS, IS, AS) and NS (no corticosteroid users). Independent sample t-tests
were used to compare corticosteroid user groups on continuous measures. Negative binomial
regression models were used to estimate the effects of corticosteroid users on count outcomes.
Pearson’s chi-square tests were used to test the relationship between corticosteroid users and
categorical measures. In the event that cell sizes dropped below n = 5, Fisher’s exact test was
used to test for statistical significance. We used Poisson regression models to assess the impact
of IBD corticosteroid use on complications, adjusting for age, male gender, Charlson
Fig 2. Escalation to corticosteroid-sparing therapy for Veterans who were intermittent corticosteroid
users (IS).
doi:10.1371/journal.pone.0158017.g002
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comorbidity index, and exposure time (IBD diagnosis date or corticosteroid initiation date to
the end of the study period). To assess escalation of therapy and DEXA scan use within one
year of corticosteroid initiation, we used logistic regression to evaluate Veteran predictors (age,
gender and GI visit pre-corticosteroid initiation) of outcomes and adjusting for clustering by
facility. In addition, we conducted a multilevel logistic regression model, adjusting for Veteran
level covariates (age, gender), to assess the facility-level variation in escalation of therapy for
Veterans among all corticosteroids users (CS, IS, AS). All data analysis was performed using
Stata 13.1 (StataCorp, College Station, TX).
Results
We identified 30,456 patients with IBD over the study period. The mean (±SD) age was 60 (15)
years. The majority of Veterans were male (94%) and Caucasian (69%). Additional baseline
characteristics are provided in Table 1 and Supplementary Table A in S1 Tables for the various
patterns of corticosteroid users.
Rates of Corticosteroid Use
Among the 30,456 Veterans, 20,575 patients (68%) did not require any corticosteroids (NS
group) during the study period for their inflammatory bowel disease or for any other coexisting
condition (see Appendix B in S1 Appendices for coexisting conditions). The remaining 32%
(n = 9,881) of Veterans received at least one fill of corticosteroids during the study period with
various patterns of corticosteroid use (see Supplementary Results “Patterns of Corticosteroid
Use” in S1 Tables). The manual chart review confirmed that ~90% of corticosteroid use was for
inflammatory bowel disease and not for other coexisting conditions. In general, the patients
who received steroids were younger than those who did not (56.2 years +/- 16 versus 62.0 years
+/- 15, p<0.001). Corticosteroid users were more likely to have a GI visit during the study
period (77.8%) compared to the NS group (43.2%), p<0.001.
Rate of Escalation to Corticosteroid-sparing Therapy for IBD
The overall rate of escalation to corticosteroid sparing medication for IBD with immunosup-
pressants or anti-TNF therapy or the combination was lower among the NS group (5.9%)
Table 1. Patient Characteristics of no corticosteroid and all corticosteroid users among IBD Veterans.
Total No Corticosteroid Users
(NS)
All Corticosteroid Users * P-value
No. of Patients, N (%) 30,456 (100) 20,575 (67.6) 9,881 (32.4)
Ulcerative Colitis, N (%) 10,664 (35.0) 7,126 (34.6) 3,538 (35.8) 0.045
Crohn’s Disease, N (%) 16,429 (53.9) 11,948 (58.1) 4,481 (45.3) <0.001
Indeterminate Colitis, N (%) 3,363 (11.0) 1,501 (7.3) 1,862 (18.8) <0.001
Male, N (%) 28,500 (93.6) 19,389 (94.2) 9,111 (92.2) <0.001
Age, years Mean (SD) 60.3 (15.3) 62.3 (14.5) 56.2 (16.0) <0.001
Race, N (%) <0.001
Caucasian 21,010 (69.0) 13,898 (67.5) 7,112 (72.0)
African American 2,097 (6.9) 1,199 (5.8) 898 (9.1)
Other 491 (1.6) 298 (1.4) 193 (2.0)
Unknown or Missing 6,858 (22.5) 5,180 (25.2) 1,678 (17.0)
Any GI Visit, N (%) 15,832 (51.9) 8,332 (40.5) 7,500 (75.9) <0.001
* Includes CS, IS, AS, OS
doi:10.1371/journal.pone.0158017.t001
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compared to the patients who received corticosteroids for their IBD (41.8%, p<0.001) (Table 2).
Escalation rates were lower among CS and IS Veterans, where only 26.2% (439/1,678) of the
patients were escalated to corticosteroid-sparing therapy in the year after their second cortico-
steroid prescription compared to the AS Veterans 47.7% (2,089/4,376) (Supplementary Table B
in S1 Tables.) Veterans with CS and IS were much more likely to step up to corticosteroid-spar-
ing therapy (immunomodulator or anti-TNF) if they had a GI visit vs. no GI visit during their
periods of corticosteroid use (unadjusted rates 69.3% vs. 30.7% in CS group; 67.3% vs. 32.7 in IS
group), p<0.001 (Table 3). Adjusting for age, male gender, steroid use group, and clustering by
facility there was an increased likelihood of corticosteroid-sparing therapy in patients with a GI
visit for those patients with a higher proportion of corticosteroid use (Fig 3).
Facility Level Variation
To examine the potential facility-level variation we conducted a multi-level logistic regression
analysis using the IBD corticosteroid groups only without any prior corticosteroid-sparing
Table 2. Corticosteroid user characteristics among Veterans with and without corticosteroids for IBD only.
Total No Corticosteroid Users
(NS)
IBD Corticosteroid Users* P-value
No. of Patients, N (%) 26,629 (100) 20,575 (77.3) 6,054 (22.7)
Study Days, median (5–95
percentile)
2,048 (518–3,174) 2,032 (508–3,173) 2,097 (540–3,182) <0.001
Rate of Escalation to
corticosteroid-sparing
therapy, N (%)
3,738 (14.0) 1,210 (5.9) 2,528 (41.8) <0.001
Type of Escalation
Medication (N = 3,738)
<0.001
Anti-TNF only 631 (2.4) 85 (7.0) 546 (21.6)
Immunomodulator only 2,727 (10.2) 1,064 (87.9) 1,663 (65.8)
Combination 380 (1.4) 61 (5.0) 319 (12.6)
Charlson Comorbidity,
Median(5–95 percentile)
0 (0–2) 0 (0–2) 0 (0–2)
*Includes CS, IS, and AS
doi:10.1371/journal.pone.0158017.t002
Table 3. Appropriate escalation to corticosteroid-sparing therapy vs. GI visit during the during corti-
costeroid evaluation period.
GI Visit
No Yes P-value
Continuous
Corticosteroid Use
(N = 1,438)
<0.001
Not Escalated 877 (83.2) 177 (16.8)
Escalated 118 (30.7) 266 (69.3)
Total 995 (69.2) 443 (30.8)
Intermittent
Corticosteroid Use
(N = 240)
<0.001
Not Escalated 149 (80.5) 36 (19.5)
Escalated 18 (32.7) 37 (67.3)
Total 167 (69.6) 73 (30.4)
doi:10.1371/journal.pone.0158017.t003
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therapy (e.g., CS, IS, AS) with the outcome of patient-level escalation (N = 5,789). Patients
were clustered within 128 VA facilities, with an average of 45 corticosteroid patients per facility
(SD = 29, min = 5, max = 133). For the purpose of these exploratory models, escalation was
defined as the introduction of any corticosteroid-sparing medication during the year after the
corticosteroid initiation date. We excluded patients who had a corticosteroid-sparing medica-
tion fill prior to the corticosteroid initiation date. The overall escalation rate was 41.2% across
the three patterns of corticosteroid use. We first ran the empty model with a random-intercept
for the facility to assess the unadjusted facility-level variation. We ran a second model adjusting
for Veteran level covariates measured prior to corticosteroid initiation (age at IBD diagnosis,
gender). The Intraclass Correlation (ICC) for the unadjusted model was 0.025 (95% CI: 0.014,
0.043) and for the adjusted model was 0.022 (95% CI: 0.012, 0.040). Thus, after adjusting for
differences in patient-level covariates, 2.2% of the total variation in escalation rates was due to
facility-level factors. The median odds ratio (MOR) was 1.30. This suggests that, given two ran-
domly selected facilities, the Veteran at a facility with a higher escalation probability has a 30%
greater odds of escalation then a similar matched (for age and gender) Veteran at a facility with
a lower escalation probability.
Corticosteroid-Associated Complications in Veterans with IBD
A descriptive comparison was used to evaluate the risk of VTE (Deep vein thrombosis [DVT]/
Pulmonary embolism [PE]), fragility fractures and infections between those exposed to cortico-
steroids for their IBD (CS, IS, AS) and those with no corticosteroid exposure. Comparisons of
the unadjusted rates for each complication in the year prior to diagnosis of IBD, in the year
Fig 3. Mean predicted likelihood of escalation to corticosteroid-sparing therapy by deciles of Total
Steroid Days among Veterans with a GI visit (square) vs. no GI visit (diamond) during the study
period. Vertical lines (slightly offset for better visibility) represent 95% Confidence Intervals. Predicted
escalation adjusted for age, male gender, the use of CS vs. IS, and clustering by facility.
doi:10.1371/journal.pone.0158017.g003
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after their study period index diagnosis of IBD and in the year after the initiation of corticoste-
roids are shown in Figs 4, 5 and 6, respectively. VTE rates more than doubled (2.1 to 4.9 per
1000 person-years) after diagnosis among patients not exposed to corticosteroids. Among
those with corticosteroid exposure, the rate of VTE almost tripled (3.1 to 9.0 per 1000 person-
years) after study period index diagnosis and increased more than 5 fold (16.9 per 1000 per-
son-years) in the year after corticosteroid exposure compared to the year prior to diagnosis.
Similarly, fragility fracture rates doubled (0.9 to 1.9 per 1000 person-years) after study period
index diagnosis among patients not exposed to corticosteroids. Among those with corticoste-
roid exposure, the rate of fragility fractures increased from 2.0 to 4.5 per 1000 person-years in
the year after corticosteroid exposure compared to the year prior to diagnosis. Among those
with corticosteroid exposure, the rate of infections increased from 40.9 to 63.9 per 1000 per-
son-years in the year after corticosteroid exposure compared to the year prior to diagnosis.
Adjusting for age, male gender, Charlson comorbidity index, we found that compared to the
year after study period index IBD diagnosis, IBD corticosteroid users (N = 6,045) had 4.68
greater probability of experiencing a VTE (IRR = 4.68, 95%CI: 3.52, 6.24, p<0.001). Similarly,
IBD corticosteroid users had a 3.7 greater probability of experiencing a fragility fracture
(IRR = 3.72, 95% CI: 2.24, 6.19, p<0.001). In addition, IBD corticosteroid users had 2.85
greater probability of infection (IRR = 2.85, 95% CI: 2.48, 3.28, p<0.001). There was no differ-
ence between the rates of complications between the CS, IS and AS groups compared to the OS
groups. (IRR = 0.83, 95%CI:0.61, 1.14, p = 0.256 for VTE, IRR = 0.83, 95%CI: 0.47, 1.47,
p = 0.533 for fragility fractures and IRR = 0.92, 95%CI: 0.77, 1.00, p = 0.318 for Infections).
Fig 4. Risk of Venothromboembolism among Veterans with IBD.
doi:10.1371/journal.pone.0158017.g004
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Fig 5. Risk of Fragility fractures among Veterans with IBD.
doi:10.1371/journal.pone.0158017.g005
Fig 6. Risk of Infections among Veterans with IBD.
doi:10.1371/journal.pone.0158017.g006
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Healthcare Maintenance: DEXA Scan Use in Veterans with IBD on
Corticosteroids
As shown in Table 4, the rates of DEXA scanning were very low in the corticosteroid cohort;
only 7.8% of these patients received a DEXA scan within one year of corticosteroid initiation,
using the above definitions. Rates were similar between age groups; 8.0% (n = 546) of patients
over 50 years old and 7.4% (n = 228) of patients 50 years and younger received a DEXA scan.
Among those that were on corticosteroids but did not have a DEXA scan (N = 9,107), only
8.2% of Veterans had a prior bisphosphonate prescription fill.
Predictors of Escalation and DEXA Scans
To evaluate the likelihood of escalation and the likelihood of obtaining DEXA scans within one
year of corticosteroid initiation we conducted logistic regression models adjusting for Veteran-
level models factors (age, gender, GI visits) as well as clustering at the facility level. The escala-
tion model included CS and IS patients only (n = 1405 (initially 1678 but excluding those that
would have had a single course of corticosteroids before continuous use)) and effect of CS vs.
IS. Factors associated with escalation of therapy among the frequent corticosteroid users were
age (OR 0.96, 95%CI: 0.95, 0.97), male gender (OR 2.00, 95%CI: 1.16, 3.46), GI visit during ste-
roid evaluation period (OR 8.01,95%CI: 5.85, 10.95) and the use of CS compared to IS (OR
2.28, 95%CI: 1.33,3.90). Factors associated with obtaining a DEXA scans among all patients on
corticosteroids (n = 9,881) were male gender (OR 0.55, 95%CI: (0.42, 0.71) and a GI visit prior
to corticosteroid initiation (OR 1.38 95%CI: 1.12, 1.70).
Discussion
In this large cohort of Veteran IBD patients, we found that one-third are treated with cortico-
steroids at least once during the study period and 15% of the total corticosteroid users were
exposed to continuous corticosteroid use. Among these patients with a prolonged exposure,
three-quarters did not receive any form of corticosteroid-sparing therapy. The negative effect
of corticosteroid exposure was seen in corticosteroid related complications such as VTE, fragil-
ity fractures and infections. Additionally, there was a low rate of utilization of DEXA scans
according to society guidelines even accounting for bisphosphonate use.
A similar but much smaller study at a tertiary care facility found that 77% of the IBD
patients had been on corticosteroids for more than 3 months and almost 60% had not had an
attempted escalation of therapy [15]. Additionally, 78% of those on corticosteroids had not
undergone DEXA scanning. Our study is a robust representation of national practice patterns
in the VHA due to the size of the cohort studied and the fact that our results are not subject to
the referral bias present at a tertiary care center. More specifically, it provides additional infor-
mation regarding patients who are not referred to a tertiary care facility for either expert care
Table 4. DEXA use among patients using corticosteroids (N = 9,881).
DEXA SCAN 1 year after corticosteroid Initiation
No Yes p
Age 0.34
 50 Yrs of Age 2,833 (92.6) 228 (7.4)
> 50 Yrs of Age 6,274 (92.0) 546 (8.0)
Total 9,107 (92.2) 774 (7.8)
*Includes CS, IS, AS, OS
doi:10.1371/journal.pone.0158017.t004
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or for more complicated disease. This study also provides a unique look at the use of corticoste-
roids in a national cohort in the modern era. An examination of the corticosteroid use of IBD
patients in Olmsted County from the 1970s to 1993 showed that approximately 40% of IBD
patients received corticosteroids during that time period [16]. Of these patients, approximately
a quarter remained corticosteroid dependent after 1 year but it should be noted that this was
prior to the era of anti-TNF therapy. In our population, approximately one-third of Veterans
required corticosteroids (CS, IS, AS & OS).
There are several limitations to our study. It is possible that our results may be inaccurate
due to an inability to account for care that occurs outside of the VHA. All Veterans are eligible
at age 65 for Medicare and VHA care. Studies of patients who have access to both systems
reveal that more than 60% utilize specialty care outside of the VHA [17]. Almost 70% of our
patients on persistent corticosteroids did not have a recorded GI visit during the period of cor-
ticosteroid use. This is most likely attributable to care sought outside of the VHA. While these
patients may seek care outside of the system, we postulate that this would only underestimate
their corticosteroid use and that many Veterans would continue to obtain prescriptions
through the VHA due to cheaper copays for the more expensive medications. In addition, a
sensitivity analysis done among Veterans who receive primary care at the VHA (based on at
least one primary care visit at the VHA within 365 days after their study period index IBD
date) showed similar patterns of results. There may be issues with the generalizability of our
findings to IBD care throughout the US due to demographic differences such as age and gen-
der. For comparison in the US overall, the median age of diagnosis of IBD is approximately 30
with a slight male predominance [18], whereas the VHA has an older population of veterans
who are predominantly male. The gender difference theoretically should not play a role in the
decision to escalate therapy or perform appropriate healthcare maintenance. This cohort’s
older average age, however, may have had some influence on the decision to escalate to more
aggressive therapy. While providers may be hesitant to escalate therapy, the risk of fragility
fractures, VTE, and other complications among the elderly on chronic corticosteroids is not
insignificant and carries significant morbidity and mortality [19, 20].
The VHA is the largest healthcare delivery system in the country and is known for deliver-
ing high quality care in those who access the system [21, 22]. This high quality care is in large
part due to the electronic medical record system which can alert providers to diagnosis-specific
quality measures. This electronic medical record system could be harnessed to improve the
quality of care among the IBD population much as it has been used to improve the care of
patients with diabetes [22]. While it would be easy to make changes to the system to improve
the rates of DEXA scanning in this population, improving the initiation of corticosteroid-spar-
ing medications would be more difficult to successfully implement. A more practical algorithm
to improving care in the VHA for this particular quality measure would be a stimulus to ensure
a recent or future GI visit when corticosteroids are prescribed for patients with an IBD diagno-
sis with an alert if such a visit is not scheduled.
Conclusion
Prolonged corticosteroid therapy for the treatment of IBD is common and may be associated
with significant harm to patients. Despite this, there was low utilization of preventative mea-
sures such as DEXA scans. No individual-level or facility-level factors were specifically associ-
ated with use of corticosteroid-sparing medications; however, a gastroenterology visit was
associated with an increased likelihood of using corticosteroid-sparing medications. Patients
with prolonged use of corticosteroids for IBD should be referred to gastroenterology early and
universal efforts to improve the delivery of high quality care should be undertaken.
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